Nupenta-CP 10 Capsules

babies: it is not applicable. lactating mother: consult your doctor before using this medication in breastfeeding.
pregnancy: consult your doctor before using this medication in pregnancy. alcohol: caution is advised while drinking alcohol with cinitapride, pantoprazole sodium.
driving: cinitapride, pantoprazole sodium capsule may cause dizziness, and it may alter your ability to drive. kidney: limited information is only available on the use of cinitapride, pantoprazole sodium capsules in patients with kidney disease.
consult your doctor before using this medication. liver: cinitapride, a pantoprazole sodium capsule, is considered safe to use in patients with liver disease.
dose adjustment is not required. consult your doctor..

Headache Diarrhea Stomach pain Flatulence Dizziness.

NUPENTA-CP capsule is a prokinetic & proton pump inhibitor medication. domperidone helps in the easy passage of food through the stomach by improving the motility of the stomach and intestines.
esomeprazole sodium relieves indigestion and heartburn caused due to acidity by reducing the acid production in stomach..

If you miss a dose of NUPENTA-CP, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• NUPENTA-CP capsule is a prokinetic & proton pump inhibitor. it is used to treat gastroesophageal reflux disease (gerd) • it should be taken before food • take this medication as prescribed by your doctor • avoid discontinuation of this medication without consulting your doctor • inform your doctor if the condition doesn’t improve even after 14 days of medication usage • avoid alcohol while taking this medication • don’t do tasks that require mental focus if you develop dizziness after taking this medication.

• pantoprazole sodium + rilpivirine: concurrent use may result in reduced rilpivirine plasma concentrations and risk of diminished therapeutic effect of rilpivirine • pantoprazole sodium + amphetamine: concurrent use may result in increased exposure to amphetamine • pantoprazole sodium + citalopram: concurrent use may result in increased citalopram exposure and risk of qt-interval prolongation • pantoprazole sodium + ketoconazole: concurrent use may result in decreased ketoconazole exposure • pantoprazole sodium + ampicillin: concurrent use may result in loss of ampicillin efficacy • cinitapride + acenocoumarol: concurrent use may result in increased risk or severity of adverse effects of cinitapride • cinitapride + ambrisentan: concurrent use may result in a decrease in the antihypertensive activities of ambrisentan • cinitapride + antipyrine: concurrent use may result in an increased risk of hypertension • cinitapride + amphetamine: concurrent use may result in an increased risk of serotonin syndrome • cinitapride + brimonidine: concurrent use may result in increased cns depressant.